US biotech company CinDome Pharma has enrolled the first patient in a phase 2 clinical trial which will evaluate its investigational gastroparesis drug deuterated domperidone (CIN-102). Considered to be a debilitating, chronic condition, gastroparesis impacts the stomach muscles and leads to improper emptying of the stomach. Deuterated domperidone (CIN-102), which has been developed through deuteration […]
Continue reading …FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint
September 14, 2019 No Comment
FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]
Continue reading …
Eisai and Biogen have decided to stop the MISSION AD1 and AD2 phase 3 clinical studies on elenbecestat in early Alzheimer’s disease (AD) owing to safety concerns, as per the latest clinical trial news. The decision has been driven by the findings of a safety review undertaken by the Data Safety Monitoring Board (DSMB), which […]
Continue reading …CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients
September 13, 2019 No Comment
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson’s Darzalex (daratumumab) (KdD) compared to Kyprolis and dexamethasone alone (Kd), called CANDOR, met its primary endpoint of progression-free survival (PFS) in multiple myeloma patients. The Amgen clinical trial featured 466 relapsed or […]
Continue reading …RESTORE clinical trial of STR001 : Strekin completes patient enrollment
September 13, 2019 No Comment
RESTORE clinical trial of STR001 : Swiss biopharma company Strekin has wrapped up patient enrollment in a phase 3 study, called RESTORE, for evaluating its small molecule STR001 in patients after a sudden sensorineural hearing loss (SSNHL) event. The late-stage trial is a global, randomized, placebo-controlled study, which will feature 165 patients at nearly 25 […]
Continue reading …ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients
September 10, 2019 No Comment
Visbiome clinical trial : ExeGi Pharma said that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be studying the company’s probiotic product Visbiome in multiple sclerosis (MS) patients in a new clinical trial. The clinical trial will look into the effects of probiotics on the gut microbiota and immune systems […]
Continue reading …Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes
September 3, 2019 No Comment
German drugmaker Boehringer Ingelheim will initiate Phase 2 clinical trial of dual-acting GLP-1/glucagon agonist BI 456906 in obesity and diabetes in late 2019. The compound in-licensed from Zealand Pharma is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors to control metabolic activities. The dual agonist BI 456906 with […]
Continue reading …
Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]
Continue reading …Satsuma doses first patient in EMERGE clinical trial of STS101 in migraine
August 26, 2019 No Comment
US biopharma company Satsuma Pharmaceuticals has dosed the first patient in its phase 3 EMERGE clinical trial of STS101 (dihydroergotamine (DHE) nasal powder) for migraine treatment. The EMERGE efficacy trial is a single-dose, double-blind, randomized, placebo-controlled, parallel-group study to be held in multiple centers. The phase 3 clinical trial will feature nearly 1,140 migraine patients […]
Continue reading …
SNK01-MX03 clinical trial : NKMax America, a US biotech company, has initiated a phase 1 trial called SNK01-MX03 to investigate its ex vivo expanded autologous natural killer cell therapeutic SNK in plaque psoriasis. In this connection, NKMax America treated the first patient in the SNK01-MX03 clinical trial, which is a single center, dose-escalation study for […]
Continue reading …
Business News Today
- Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL
- Tor field : ConocoPhillips gets PSA nod for production drilling
- Miami Grill seeks out franchise partners in Jacksonville, Florida
- GE Healthcare unveils Serena Bright mammography solution for biopsy
- BIG-P gas project : Premier Oil draws first gas from Indonesian gas project
- Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma
- PepsiCo to acquire PopCorners snacks owner BFY Brands
- Venture Global’s Plaquemines LNG Project gets DOE nod for LNG exports
- Y-mAbs begins roll-out of BLA of naxitamab to FDA for neuroblastoma
- Energy Absolute’s Hanuman Wind Farm in Thailand secures ADB funding
